Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in recurrent or metastatic cervical cancer
ChiCTR1800016676Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800016676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016676.